Reported Saturday, Purple Biotech Revealed Results From A Phase 2 Study At ASCO 2024, Showing CM24 Improved Overall Survival And Other Efficacy Endpoints In Pancreatic Cancer
Portfolio Pulse from Benzinga Newsdesk
Purple Biotech revealed positive Phase 2 study results for CM24 at ASCO 2024, showing significant improvements in overall survival and other efficacy endpoints in pancreatic cancer patients.
June 03, 2024 | 8:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Purple Biotech's Phase 2 study results for CM24 show a 26% reduction in risk of death and a 28% reduction in risk of progression or death in pancreatic cancer patients, along with improved overall survival and progression-free survival.
The positive Phase 2 study results for CM24 indicate a significant improvement in treatment outcomes for pancreatic cancer patients, which is likely to boost investor confidence and positively impact Purple Biotech's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100